Patents by Inventor Matthew R. Kaller

Matthew R. Kaller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
    Publication number: 20240059703
    Abstract: Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 22, 2024
    Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, JOSEPHINE ESHON, DAVID HUANG, MATTHEW R. KALLER, HEEJUN LEE, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M MEDINA, ALEXANDER J. PICKRELL, JOHN C. STELLWAGEN, ZHEN SUN, NURIA A. TAMAYO, WENHAN ZHANG, KAI ZHU
  • HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
    Publication number: 20230406860
    Abstract: The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 21, 2023
    Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, MATTHEW R. KALLER, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M. MEDINA, ALEXANDER J. PICKRELL, NURIA A. TAMAYO, KAI ZHU
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • Compounds that inhibits MCL-1 protein
    Patent number: 11224601
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: January 18, 2022
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • Heteroaryl-substituted triazoles as APJ receptor agonists
    Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10821115
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 3, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200171043
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10632128
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 28, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190381064
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • Triazole agonists of the APJ receptor
    Patent number: 10221162
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 5, 2019
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20180319773
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 8, 2018
    Applicant: AMGEN INC.
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20180289720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 28, 2018
    Publication date: October 11, 2018
    Applicant: Amgen Inc.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • Methods of treating heart failure
    Patent number: 10058550
    Abstract: Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 28, 2018
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Zice Fu, Julie Anne Heath, Daniel B. Horne, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Zhihua Ma, Jeffrey T. Mihalic, Gayathri Swaminath, Xiaodong Wang, Wen-Chen Yeh
  • Triazole agonists of the APJ receptor
    Patent number: 9868721
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: January 16, 2018
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Intermediates for preparing triazole agonists of the APJ receptor
    Patent number: 9845310
    Abstract: Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 19, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Simon J. Hedley
  • METHODS OF TREATING HEART FAILURE
    Publication number: 20170281625
    Abstract: Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 5, 2017
    Inventors: Ning Chen, Xiaoqi CHEN, Yinhong CHEN, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Zhihua MA, Jeffrey T. MIHALIC, Gayathri SWAMINATH, Xiaodong WANG, Wen-Chen YEH
  • Methods for preparing triazole agonists of the APJ receptor
    Patent number: 9751864
    Abstract: Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: September 5, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Xiaodong Wang, Kevin Yang, Mikkel V. DeBenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd
  • Triazole agonists of the APJ receptor
    Patent number: 9745286
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 29, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Triazole agonists of the APJ receptor
    Patent number: 9656997
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: May 23, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Intermediates for preparing triazole agonists of the APJ receptor
    Patent number: 9656998
    Abstract: Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: May 23, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd